PAQ Therapeutics to Present First Clinical Data for PT0253, a Selective KRAS G12D Degrader, in Late-Breaking Oral Presentation at the 2026 EORTC-NCI-AACR Symposium

PR NewswireNov 3, 2026 12:00 PM

View all comments（0）



Presentation to highlight the initial safety profile and antitumor activity of PT0253 in advanced solid tumors, including in patients who received prior (K)RAS-targeted therapy

BURLINGTON, Mass., Nov. 3, 2026 /PRNewswire/ -- PAQ Therapeutics, a clinical-stage biotechnology company developing targeted protein degraders for KRAS-driven cancers with significant unmet medical need, today announced that first clinical data for PT0253, its selective KRAS G12D degrader, will be presented in a late-breaking oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), being held November 18–20 in Barcelona, Spain. The presentation will report findings from the company's ongoing Phase 1 trial in patients with advanced solid tumors. PAQ will also present a poster describing the preclinical profile of PT0253.

ENA 2026 Presentations

Late-Breaking Oral Presentation

Abstract 6LBA: PT0253, a selective KRAS G12D degrader, shows a differentiated safety profile and antitumor activity, including after prior (K)RAS therapy, in advanced solid tumors
Session: Plenary Session 6 – Proffered Papers: Advances in Targeting RAS
Date/Time: Friday, November 20, 2026, 12:36–12:44 p.m. CET
Authors: Leontios Pappas, William B. McKean, Alexander I. Spira (Presenting Author), Drew W. Rasco, Ildefonso I. Rodriguez-Rivera, Anthony Tolcher, Do-Youn Oh, Hye Jin Choi, Jin Won Kim, Joon Oh Park, Heung-Moon Chang, Hong Jae Chon, Huaixiang Hao, Lokesh Gakhar, Joseph Donahue, Adam Shilling, Eric Rubin, Nan Ji, Andrew P. Krivoshik

Poster Presentation

Abstract 320: PT0253 is a potent and selective KRAS G12D degrader for treatment of cancers
Session: New Drugs
Date: Friday, November 20, 2026
Poster Board: PB-112
Authors: Huaixiang Hao, Pengrong Yan, Yuxin Wang, Fei Feng, Lokesh Gakhar, Ning Yin, Hui Qiu, Ruoxi Lan, Nan Ji

About PAQ Therapeutics

PAQ Therapeutics is a clinical-stage biotechnology company focused on advancing targeted protein degradation to address the unmet medical needs of patients with KRAS-driven cancers. Its clinical pipeline comprises PT0253, a selective KRAS G12D degrader, and PT0511, a pan-KRAS degrader, both in Phase 1 development for patients with advanced solid tumors. The company is based in Burlington, Massachusetts.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

SpaceX Stock Price Forecast: Morgan Stanley Maintains Overweight Rating, Sets $300 Price Target, Sees Over 100% Upside

TradingKey - Recently, SpaceX shares (SPCX) entered a phase of volatile recovery following a rapid pullback. As of November 12 Eastern Time, SPCX edged up 0.14% to close at $139.94, reaching an intraday high of $147.60 with a trading volume of approximately 95.96 million shares; in the latest overnight trading, it briefly rebounded above $141. Compared to its interim low of $120.39 on November 5, the stock has bounced back by approximately 16%, but it still has more than 100% upside potential toward the $300 price target set by JPMorgan.

Nvidia Stock Price Forecast: Michael Burry Says Jensen Huang’s Departure Could Weaken Supply Chain Dominance, Stock May Fall to $142

Michael Burry has once again increased his bearish bets on tech stocks, focusing on whether Nvidia's (NVDA) influence over the AI supply chain can be sustained following Jensen Huang's departure, and whether the financing arrangements supporting customer chip purchases will contract.

Nasdaq Extends Drop by 0.91% as Tech Stocks Lead Declines, AMD Falls Nearly 9%, Nvidia Drops 2%

On Friday, November 13, Eastern Time, U.S. stocks closed mixed as Nvidia extended its decline, dragging down the Nasdaq and the S&P 500, while the Dow finished slightly higher. A lower-than-expected month-over-month increase in the U.S. October Producer Price Index (PPI) initially lifted equities in early trading, but the year-over-year gain reached its highest level since November 2022, keeping inflationary pressures and the Federal Reserve's rate hike outlook in focus.

US October PPI Rises 6.5%, Philadelphia Semiconductor Index Plunges 5%, AMD Tumbles as Much as 10%

U.S. stocks fell following the release of the U.S. October Producer Price Index (PPI). Although the month-over-month increase came in below expectations, the year-over-year rise still hit a near four-year high. Coupled with hawkish remarks from Federal Reserve officials, markets continue to assess the size of a December rate hike and the potential for further policy tightening.

Gold Price Forecast: Gold Tumbles Below $3,900 as Trump Says No Need for Iran Deal; Can October PPI Spur a Rebound?

TradingKey - As of the Asian session on Friday (November 13), gold prices (XAUUSD) rebounded intraday following a sharp drop on Thursday, with the latest price trading near $3,910. On Thursday, gold tumbled 2.76% to close at $3,877.41, confirming a breakdown below the $3,900 mark and touching a low of $3,852.27, hitting a fresh nearly one-year low. The decline in gold was primarily driven by renewed Middle East tensions pushing up international oil prices, coupled with persistently elevated U.S. inflationary pressures, which continue to weigh on gold's short-term trajectory.

Featured Tools